6 results
To explore the efficacy and safety of an oral IP receptor agonist in an inoperable or persistent/recurrent CTEPH population treated with standard of care.
To determine whether addition of selexipag to current PAH therapy improves exercise capacity, imaging parameters and quality of life, delays time-to-first-PAH-related morbidity and mortality, prevents worsening of World Health Organization…
1. To explore the pharmacokinetics (PK) of intra-vaginal delivery of gonadorelin and oxybutynin. 2. To assess the safety and tolerability of gonadorelin and oxybutynin delivery with a prototype intra-vaginal ring.
The aim of the present study is to investigate whether selexipag could be helpful to treat patients with another form of PH called sarcoidosis-associated pulmonary hypertension (SAPH).
Objectives (all are exploratory):• To measure and analyze 89Zr-Df-IAB22M2C uptake cluster of (CD8+ PET signal) at and between baseline and post-treatment in tumor lesions and reference normal tissues, including T-cell rich tissues, using PET imaging…
Main objective:To assess the effects of selexipag on right ventricular (RV) function in participants with PAH.Secondary objectives:- To further assess the effects of selexipag on RV function using MRI.- To assess the effects of selexipag on disease…